This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.
Inclusion Criteria:
Exclusion Criteria:
Phoenix, Arizona 85032, United States
Little Rock, Arkansas 72205, United States
Artesia, California 90701, United States
Garden Grove, California 92843, United States
Glendale, California 91205, United States
Irvine, California 92604, United States
La Jolla, California 92037, United States
Mission Hills, California 91345, United States
Newport Beach, California 92663, United States
Petaluma, California 94954, United States
Centennial, Colorado 80112, United States
Colorado Springs, Colorado 80907, United States
Danbury, Connecticut 06810, United States
Bradenton, Florida 34209, United States
Bloomingdale, Illinois 60108, United States
New Albany, Indiana 47150, United States
Overland Park, Kansas 66061, United States
Louisville, Kentucky 40217, United States
Chesterfield, Missouri 63017, United States
Kansas City, Missouri 64111, United States
St Louis, Missouri 63131, United States
Washington, Missouri 63090, United States
South Orange, New Jersey 07079, United States
Rochester, New York 14618, United States
Rockville Centre, New York 11570, United States
Wantagh, New York 11793, United States
High Point, North Carolina 27262, United States
Eugene, Oregon 97401, United States
Cedar Park, Texas 78613, United States
Houston, Texas 77204, United States
Salt Lake City, Utah 84107, United States
Salt Lake City, Utah 84117, United States
Norfolk, Virginia 23502, United States